在吸烟患者中对Levamlodipine Besylate的模型告知精确剂量
Guoxing Li1, Ying Guan2, YingYing Yang3
1Phase I Clinical Trial Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Drug design, development and therapy
|April 29, 2025
概括
这项研究发现,服用莱瓦姆洛迪平甲基酸盐的患者估计较低的淋巴球过率 (eGFR) 和尿酸 (UA) 水平与较低的清除相关,这表明吸烟者可能需要更高的初始剂量. 尼古丁和PAH酶效应并不显著.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药理动力学 药理动力学
背景情况:
- 列瓦姆洛迪平酸盐是一种用于高血压的通道阻塞剂.
- 众所周知,吸烟会影响药物代谢和疗效.
- 了解影响莱瓦姆洛迪平酸度的因素对于优化吸烟者的治疗至关重要.
研究的目的:
- 调查尼古丁,人口统计学,生物化学标记物和遗传多态性对吸烟者的莱瓦姆洛迪平酸盐药理动力学 (PK) 和药理动力学 (PD) 的影响.
- 开发一个人群PK/PD模型,用于准确的药物剂量在吸烟患者接受Levamlodipine单一治疗.
主要方法:
- 一项前性研究招募了43名接受莱瓦姆洛迪平单一治疗的患者.
- 使用单个组件的PK模型和直接效应模型开发了一个人群PK/PD模型.
- 分析的共变量包括尼古丁度,人口统计,生物化学指数 (ALT,AST,ALB,UA,eGFR) 和遗传多态.
主要成果:
- 种群PK/PD模型显示了V,CL,E0,Imax和IC50.50的典型值.
- 较低的估计淋巴膜过率 (eGFR) 和尿酸 (UA) 水平与较低的莱瓦姆洛迪平清除率 (CL) 有显著的关联.
- 尼古丁度和PAH代谢酶多态性并没有显著影响该队列中的PK/PD.
结论:
- 患有较低EGFR和UA水平的患者可能需要更高的Levamlodipine酸盐初始剂量以获得有效的单一疗法.
- 需要使用更大的数据集进行进一步的研究,以充分阐明尼古丁和遗传因素对吸烟者中levamlodipine besylate PK/PD的影响.
相关概念视频
Rational Dosage Regimen: Maintenance Dose and Loading Dose
3.6K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.6K
Dosage Regimen: Fixed Dose
1.8K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.8K
Drug Dosage Regimen: Overview
3.3K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.3K
Renal Failure: Dose Adjustments
34
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
34
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
36
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
36
Analysis of Population Pharmacokinetic Data
190
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
190


